Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00814372 · ClinicalTrials.gov registry record · Phase 2
Evaluate Safety and Effectiveness of MBX-102 in Type 2 Diabetes Patients With Poor Glycemic Control on Metformin
A Phase 2 study, sponsored by Gilead Sciences.
- Terminated
- Registry status
- Phase 2
- Development phase
- 242
- Enrollment target
NCT00814372 is a Phase 2 study that was terminated before completion, run by Gilead Sciences. The registered enrollment target is 242 participants.
The verdict
NCT00814372, a Phase 2 study, was terminated before completion, sponsored by Gilead Sciences.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 242 participants
- Enrollment target
Study Summary
To define the relative efficacy, safety and tolerability profiles of oral daily MBX-102 at daily doses of 400 and 600 mg vs. placebo and Actos® 30 mg (up-titrated to 45 mg after 8 weeks) when administered for up to 24 weeks in patients inadequately controlled with a stable dose of metformin (≥ 1500 mg/day).
Interventions
- DRUG Placebo
- DRUG Metformin
- DRUG Actos
- DRUG MBX-102
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 242 participants |
| Start Date | 2008-12 |
| Est. Completion | 2010-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00814372
The ClinicalTrials.gov registry entry for NCT00814372 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 242 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00814372 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00814372 about?
NCT00814372 is a clinical study titled "Evaluate Safety and Effectiveness of MBX-102 in Type 2 Diabetes Patients With Poor Glycemic Control on Metformin". To define the relative efficacy, safety and tolerability profiles of oral daily MBX-102 at daily doses of 400 and 600 mg vs. placebo and Actos® 30 mg (up-titrated to 45 mg after 8 weeks) when administered for up to 24 weeks in patients inadequately controlled with a stable dose of metformin (≥ 1500 ...
What is the current status of trial NCT00814372?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 242 participants. The study started on 2008-12. Estimated completion is 2010-02.
What interventions are being tested in trial NCT00814372?
The interventions under investigation include: Placebo (DRUG), Metformin (DRUG), Actos (DRUG), MBX-102 (DRUG).
Who is sponsoring clinical trial NCT00814372?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.